development
  
 

    

          
    
    

      

        
      


      
      
        
        
                  

            Period. 29 September - 5 October 2020          

                
       
    


    
    
    

    
          
    

  • The researchers behind Moderna’s COVID-19 vaccine candidate (MRNA1273) published a new paper in the New England Journal of Medicine with preliminary results from its Stage 3 Human Trials. Based on 40 participants over the age of 56 that were recruited for the study, the authors conclude that the at-risk cohort has reacted very well to the vaccine candidate when given two doses of the vaccine four weeks apart. After the second immunization, the researchers noted that neutralizing antibody responses were recorded in all participants using several different methods, while binding and antibody responses were similar to those reported in those aged between 18 and 55 years old. Side effects were also reported to be “mild or moderate” in severity with common symptoms including fatigue, chills, headache, myalgia and injection site pain.
    • 




    
     
      
      
      
            
      
              

        

          
This development is part of the digest;